Design of an Ara h 2 hypoallergen from conformational epitopes
- 2 January 2024
- journal article
- research article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (1) , 46-55
Abstract
Introduction: Adverse reactions are relatively common during peanut oral immunotherapy. To reduce the risk to the patient, some researchers have proposed modifying the allergen to reduce IgE reactivity, creating a putative hypoallergen. Analysis of recently cloned human IgG from patients treated with peanut immunotherapy suggested that there are three common conformational epitopes for the major peanut allergen Ara h 2. We sought to test if structural information on these epitopes could indicate mutagenesis targets for designing a hypoallergen and evaluated the reduction in IgE binding via immunochemistry and a mouse model of passive cutaneous anaphylaxis (PCA).Methods: X‐ray crystallography characterized the conformational epitopes in detail, followed by mutational analysis of key residues to modify monoclonal antibody (mAb) and serum IgE binding, assessed by ELISA and biolayer interferometry. A designed Ara h 2 hypoallergen was tested for reduced vascularization in mouse PCA experiments using pooled peanut allergic patient serum.Results: A ternary crystal structure of Ara h 2 in complex with patient antibodies 13T1 and 13T5 was determined. Site‐specific mutants were designed that reduced 13T1, 13T5, and 22S1 mAbs binding by orders of magnitude. By combining designed mutations from the three major conformational bins, a hexamutant (Ara h 2 E46R, E89R, E97R, E114R, Q146A, R147E) was created that reduced IgE binding in serum from allergic patients. Further, in the PCA model where mice were primed with peanut allergic patient serum, reactivity upon allergen challenge was significantly decreased using the hexamutant.Conclusion: These studies demonstrate that prior knowledge of common conformational epitopes can be used to engineer reduced IgE reactivity, an important first step in hypoallergen design.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- National Institute of Environmental Health Sciences
This publication has 37 references indexed in Scilit:
- Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific ImmunotherapyCurrent Treatment Options in Allergy, 2014
- Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapyJournal of Allergy and Clinical Immunology, 2014
- Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergyJournal of Allergy and Clinical Immunology, 2012
- Reshaping the Bet v 1 fold modulates TH polarizationJournal of Allergy and Clinical Immunology, 2011
- Ara h 2: crystal structure and IgE binding distinguish two subpopulations of peanut allergic patients by epitope diversityAllergy, 2011
- Prevalence and distribution of sensitization to foods in the European Community Respiratory Health Survey: a EuroPrevall analysisAllergy, 2010
- Identification and characterization of a hypoallergenic ortholog of Ara h 2.01Plant Molecular Biology, 2008
- Hydrogen Exchange Nuclear Magnetic Resonance Spectroscopy Mapping of Antibody Epitopes on the House Dust Mite Allergen Der p 2Journal of Biological Chemistry, 2001
- The natural history of peanut allergyJournal of Allergy and Clinical Immunology, 2001
- Recombinant allergens for immunotherapy: A Der p 2 variant with reduced IgE reactivity retains T-cell epitopes☆☆☆★★★Journal of Allergy and Clinical Immunology, 1998